Skip to main content

Advertisement

Table 3 Multivariate models without NLR for patients with advanced NPC

From: Prognostic value of neutrophil-to-lymphocyte ratio in advanced nasopharyngeal carcinoma: a large institution-based cohort study from an endemic area

Endpoint Variable HR 95% CI for HR P value
OS
  Age (≤ 45 vs. >  45) 1.64 1.25–2.14 < 0.001
  Sex (Male vs. Female) 1.3 0.90–1.88 0.158
  Smoking history (No vs. Yes) 1.09 0.82–1.46 0.553
  T stage (T1–2 vs. T3–4) 1.42 1.04–1.94 0.029
  N stage (N0–1 vs. N2–3) 2.84 2.18–3.69 < 0.001
DMFS
  Sex (Male vs. Female) 1.34 0.95–1.89 0.098
  N stage (N0–1 vs. N2–3) 3.49 2.64–4.61 < 0.001
LRFS
  Age (≤ 45 vs. >  45) 1.4 1.02–1.92 0.035
  N stage (N0–1 vs. N2–3) 1.35 0.97–1.88 0.077
PFS
  Age (≤ 45 vs. >  45) 1.42 1.15–1.77 0.001
  Family history (No vs. Yes) 1.17 0.92–1.50 0.205
  Smoking history (No vs. Yes) 1.11 0.89–1.38 0.34
  T stage (T1–2 vs. T3–4) 1.28 1.00–1.65 0.048
  N stage (N0–1 vs. N2–3) 2.24 1.81–2.78 < 0.001
  1. Abbreviation: OS overall survival, DMFS distant metastasis-free survival, LRFS locoregional relapse-free survival, PFS progression-free survival, RT radiotherapy, CCRT concurrent chemoradiotherapy, NACT neoadjuvant chemotherapy, NLR neutrophil-to-lymphocyte ratio, HR rate ratio, CI confidence interval